Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.

Akitaka MakiyamaKohei ArimizuGen HiranoChinatsu MakiyamaYuzo MatsushitaTsuyoshi ShirakawaHirofumi OhmuraMasato KomodaKeita UchinoKyoko InadomiShuji AritaHiroshi AriyamaHitoshi KusabaYudai ShinoharaMiyuki KuwayamaTatsuhiro KajitaniHisanobu OdaTaito EsakiKoichi AkashiEishi Baba

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2017)

Irinotecan monotherapy was relatively safely performed as salvage-line treatment for AGC in Japanese clinical practice. Careful patient selection and intensive modification of the dose of irinotecan might possibly be associated with favorable survival.

Keyphrases

combination therapy
clinical practice
open label
squamous cell carcinoma
smoking cessation
free survival